National Institute for Clinical Excellence NICE

In 1997, the British Government proposed in the White Paper The New NHSiModern and Dependable that the National Institute for Clinical Excellence (NICE) should be established,- a proposal endorsed by Griffin. ... 

The National Institute for Clinical Excellence (NICE). Available HTTP (accessed 2 April 2003). 

Johnston, S. (2004), Ovarian cancer Review of the national institute for clinical excellence (NICE) guidance recommendations, Cancer Inv., 22,730-742. 

Zanamivir was one of the first medicines to be the subject of a technology appraisal by the National Institute for Clinical Excellence (NICE) in the UK. NICE recommends that it be reserved for at-risk patients (those with chronic respiratory or cardiovascular disease, immunosuppression or diabetes mellitus, or over the age of 65) when virological... 

The UK National Institute for Clinical Excellence (NICE) recommends that donepezil, galantamine and rivastigmine should be available as adjuvant therapy for those with a MMSE score above 12 points, subject to the following conditions ... 

Funded by the government, the National Institute for Clinical Excellence (NICE) was set up as a Special Health Authority in the United Kingdom in 1999 and, as such, it is a part of the National Health Service (NHS). It was set up to provide the NHS (patients, health professionals, and the public) with authoritative, robust and reliable guidance on current best practice. Its key functions are to appraise the clinical benefits and the costs of those (health care) interventions and to make recommendations. Guidance is issued from each appraisal based on the clinical benefits,... 

In 1999 the UK government established the National Institute for Clinical Excellence (NICE) as a special health authority. The government s objectives behind NICE were to encourage the faster uptake of effective new treatments, to promote more equitable access to treatments and to improve the use of NHS resources. In one sense industry welcomed the introduction of NICE in that the UK has one of the slowest uptakes of innovative therapies across Europe, has some of the highest rates of cancer and heart disease and postcode prescribing persists. The industry, however, remains concerned about the impact NICE will have on the pharmaceutical industry in the UK. Industry s concern is that, far from encouraging faster... 

National Institutes for Clinical Excellence (NICE). Midcity Place, 71 High Holbom, London WCIV 6NA, U.K Phone +44-20-7067-5800, Fax +44-20-7067-5801. E-mail nice nice.nhs.uk. URL http //www.nice.org.uk. Part of England s National Health Service, NICE was set up as a special health authority for England and Wales on April 1, 1999. Its goal is to provide refiable and authoritative best-practice guidelines for patients, health professionals, and the public. Complete published guidelines on cfinical practice and interventional procedures may be downloaded in PDF format from the NICE Web site. 

In the UK the National Institute for Clinical Excellence (NICE) has given guidance supporting the use of olanzapine and valproate semisodium in acute mania. NICE guidelines on the treatment of bipolar disorder are expected in June 2006. 

In the UK, National Institute for Clinical Excellence (NICE) guidelines for treating panic disorder and GAD are due to be published in late 2004. 

Funding/implementation issues led to variable availability in the UK. Subject of national guideline from National Institute for Clinical Excellence (NICE) requiring availability of licensed anticholinesterases (donepezil, rivastigmine, galantamine) subject to specific requirements ... 

UK national institute for clinical excellence (NICE) 1720 Ultrafiltration 159... 

The organizations that actually pay for medicines — governments, insurers and so on—have only recently started to use the power conferred by their expenditure. A consequence is that a drug company has not only to show that its new product is safe and works, but also that it is cost-effective. In Australia, this has been spelled out in legislation. Since 1993, any drug submitted for approval there must be accompanied not only by the results of clinical trials but also by an economic impact analysis. In 1999 the UK set up a National Institute for Clinical Excellence (NICE) to advise the National Health Service on the cost-effectiveness of health care technologies. Other countries ask formally or informally for pharmacoeconomic analysis. Economic impacts can be measured in a variety of ways, for example, cost-effectiveness, cost-utility or fuU cost-benefit studies. 

---